|Bid||48.84 x 1000|
|Ask||48.85 x 800|
|Day's range||48.77 - 49.10|
|52-week range||36.91 - 58.10|
|Beta (5Y monthly)||0.41|
|PE ratio (TTM)||8.37|
|Forward dividend & yield||1.75 (3.72%)|
|Ex-dividend date||26 May 2022|
|1y target est||63.50|
Sanofi (SNY) closed the most recent trading day at $48.56, moving +1.17% from the previous trading session.
Sanofi (SNY) and Regeneron's Dupixent becomes the first and only targeted medicine approved to treat severe atopic dermatitis in kids as young as six months old in Europe.
Dupixent® (dupilumab) approved by European Commission as first and only targeted medicine for children as young as six months old with severe atopic dermatitis Approximately seven times as many patients aged 6 months to 5 years with severe atopic dermatitis treated with Dupixent experienced clear or almost clear skin and reduced overall disease severity compared to placeboPatients treated with Dupixent achieved rapid itch reduction as early as three weeks after start of therapy, with significant